Efficacy and Safety of adjunctive Perampanel in a prospective, real‐world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal‐onset Epilepsy: Study 508

Documenti analoghi

• Efficacy and safety of perampanel as first adjunctive therapy in patients with focal‐onset seizures or generalized tonic‐clonic seizures in four post‐marketing studies across regions
  di: Stefano Meletti, et al.
  Pubblicazione: (2025)
• Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study
  di: Haiyan Ma, et al.
  Pubblicazione: (2025)
• Real‐world use of adjunctive perampanel for focal‐onset seizures in Italy: A mirroring clinical practice study of perampanel in adults and adolescents ( AMPA )
  di: Alfredo D'Aniello, et al.
  Pubblicazione: (2025)
• Cross‐cultural application of the International Classification of Cognitive Disorders in Epilepsy (IC‐CoDE)
  di: Urvashi Shah, et al.
  Pubblicazione: (2024)
• Effectiveness and safety of adjunctive cenobamate in people with focal‐onset epilepsy: Interim results after 24‐week observational period from the BLESS study
  di: Simona Lattanzi, et al.
  Pubblicazione: (2025)